GeneDx posts 41% revenue growth, issues 2026 guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
January 12, 2026 7:30 AM ESTExpects full year 2025 revenues of $427 million, with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit) Expects fourth quarter 2025 revenues of $121 million, with exome and genome revenue up 32% (43% excluding a one-time 2024 benefit) Expects full year 2025 exome and genome volume growth of more than 30%, with the fourth quarter 2025 accelerating to 34.3% Expects full year 2025 and fourth quarter 2025 adjusted gross margin of 71% Issues full year 2026 guidance expecting revenues between $540 and $555 million, with 33-35% exome and genome growth
GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx Holdings Corp. (Nasdaq:... More
